marked.bio

Company

Shenzhen TargetRx

3 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers; 1 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

deulorlatinib 3crizotinib 1

Trials

3 of 3 trials shown

  1. TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)

    Active, not recruiting Phase 3 Shenzhen TargetRx Started 2023Primary completion 2026-04 NCT06082635

    deulorlatinibcrizotinib FDA EU

    Diagnosed as incurable stage IIIB - IV ALK-positive NSCLC;

    ALK fusionNon Small Cell Lung Cancer

  2. TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)

    Active, not recruiting Phase 2 Shenzhen TargetRx Started 2023Primary completion 2024-12 NCT05955391

    deulorlatinib

    With ALK-positive advanced inoperable NSCLC and having disease progression or intolerance after continuous …

    ALK fusionNon-small Cell Lung Cancer

  3. TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)

    Active, not recruiting Phase 1 Shenzhen TargetRx Started 2021Primary completion 2025-08 NCT05441956

    deulorlatinib

    Diagnosis of ALK-positive or ROS1-positive advanced NSCLC by histopathology or cytology in a Grade-A tertiary hospi…

    ALK fusionROS1 fusionNon-small Cell Lung Cancer